UPDATE: Goldman Sachs Raises PT on Accretive Health to $21 (AH)

Goldman Sachs is out with its report today on Accretive Health

, raising its PT from $14 to $21. In a note to clients, Goldman Sachs states, "We increase our 12 month price target to $21 from $14, which is based on a blend of our EV/EBITDA (50%), PEG (30%), and DCF (20%) valuation analyses. Our price target rises given we roll forward to 2012E estimates (from 2011E) and assume greater long-term EBITDA margin expansion." Goldman Sachs maintains Neutral on AH. Shares of AH closed Wednesday at $20.00.